Brief: Amylyx Pharmaceuticals Announces Positive Long-Term Results From Phase 2 Helios Clinical Trial Of Amx0035 In People With Wolfram Syndrome
12/05/2025 12:28
May 12 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O: AMYLYX PHARMACEUTICALS ANNOUNCES POSITIVE LONG-TERM RESULTS FROM PHASE 2 HELIOS CLINICAL TRIAL OF AMX0035 IN PEOPLE WITH WOLFRAM SYNDROME AMYLYX PHARMACEUTICALS INC - AMX0035 WELL-TOLERATED IN ALL PARTICIPANTS AMYLYX PHARMACEUTICALS INC - EXPECTS CASH RUNWAY THROUGH END OF 2026 Source text: ID:nBw5tRD6va Further company coverage: AMLX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amylyx Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-LSI Industries, SiTime, Andersen Group
U.S. STOCKS ON THE MOVE-Apple, Hims & Hers Health, Sysco
U.S. STOCKS ON THE MOVE-Nordson, Nebius, Deere
Amylyx dips after increased $500 mln stock sale to fund blood sugar drug
Brief: Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock